Klebsazolicin

Klebsazolicin is a ribosomally synthesized and post-translationally modified peptide (RiPP) that was discovered in 2017. It is produced by Klebsiella pneumoniae, a Gram-negative bacteria that is commonly associated with hospital-acquired infections. Klebsazolicin is a unique type of antibiotic that targets the ribosome, the protein-making machinery of the cell, in a novel way.

Discovery

Klebsazolicin was discovered by a team of researchers at the University of Illinois and the Russian Academy of Sciences. The team used a combination of genomics, bioinformatics, and biochemistry to identify and characterize the new antibiotic.

Mechanism of Action

Klebsazolicin works by binding to the ribosomal exit tunnel, a narrow channel through which newly synthesized proteins exit the ribosome. This binding blocks the exit of the growing protein chain, effectively halting protein synthesis and leading to cell death. This mechanism of action is unique among known antibiotics.

Potential Applications

Due to its novel mechanism of action, klebsazolicin has potential as a new treatment for multidrug-resistant bacterial infections. However, further research is needed to determine its safety and efficacy in humans.

See Also

• Antibiotics
• Klebsiella pneumoniae
• Ribosome
• Multidrug resistance

This article is a stub related to medicine. You can help WikiMD by expanding it!